RxDoctor Payments DataLook up a doctor →

Quang Nguyen, DO

Endocrinology, Diabetes & Metabolism · Henderson, NVNPI 1053516542

Payments from drug & device makers

$2,893,907in general payments, 2019–2025

Across 2,208 payments — averaging $1310.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$1.2M
  • Eli Lilly$575K
  • Novartis$350K
  • Amgen$313K
  • Novo Nordisk$167K
  • Mannkind Corporation$86K
  • plus $233K from 54 others
$80,184in research payments, 2019–2025

Across 8 payments — averaging $10,023 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$73K
  • Novartis$7K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Dexcom, Inc.147$1,171,460
Eli Lilly6$574,849
Novartis37$349,633
Amgen(2 entities)121$312,533
Novo Nordisk309$167,083
Mannkind Corporation128$85,503
Lilly USA, LLC173$55,893
AstraZeneca(2 entities)193$44,717
Sanofi-aventis U.S. LLC138$43,582
Globus Medical4$42,392
Nevro Corp.16$21,730
Neurocrine Biosciences, Inc.90$8,224
Abbott112$2,534
Boehringer Ingelheim61$2,449
AbbVie(2 entities)101$1,521
Antares Pharma, Inc.70$980
Xeris Pharmaceuticals, Inc.53$889
Radius Health, Inc.43$787
Corcept Therapeutics41$706
Bayer63$699
IBSA Pharma Inc.26$496
Medtronic(2 entities)34$466
Recordati_rare_diseases_inc.17$451
Ultragenyx Pharmaceutical Inc.12$331
Insulet Corporation15$316
Lifescan, Inc.11$248
Esperion Therapeutics, Inc.13$240
Amarin Pharma, Inc.17$238
Tandem Diabetes Care, Inc.12$203
Astellas Pharma US Inc6$188
Merck11$183
Kyowa Kirin, Inc.6$147
Almatica Pharma LLC7$133
Companion Medical, Inc.8$119
Chiasma, Inc.1$117
Chiesi USA, Inc.5$116
Shire North American Group Inc7$112
Biohaven Pharmaceuticals, Inc.14$112
EUSA Pharma (US) LLC4$110
BETA Bionics, Inc.4$103
BD6$102
Pfizer6$95
Averitas Pharma Inc.5$89
Biohaven Pharmaceutical Holding Company Ltd.6$83
Alfasigma USA, Inc.4$79
Ascensia Diabetes Care US Inc.4$70
Nestle Healthcare Nutrition Inc.3$62
Acerus Pharmaceuticals Corporation2$59
Daiichi Sankyo Inc.3$57
Amphastar Pharmaceuticals, Inc.3$54
Johnson & Johnson3$46
Amryt Pharma Holdings Ltd2$45
Rhythm Pharmaceuticals, Inc.2$43
Halozyme Inc2$42
Regeneron Healthcare Solutions, Inc.2$37
Gilead1$34
Ionis Pharmaceuticals, Inc.1$31
Embecta Corp.2$29
Soleno Therapeutics, Inc.1$28
Amneal Pharmaceuticals LLC2$28

How this compares

$2,893,907 in reported general payments places this provider in the 95th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.

See all endocrinology, diabetes & metabolism providers in Nevada →

Medicare billing

Part B allowed, 2024
$704,406
Medicare patients
1,275
Services billed
11,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Henderson

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →